Axsome Therapeutics shares soar on 'breakthrough' FDA status for depression drug
Axsome Therapeutics Inc. shares AXSM, -12.24% jumped 7% in premarket trade Wednesday, after the U.S. Food and Drug Administration granted breakthrough therapy designation to a treatment for major depressive disorder.
Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
FDA-approved 'breakthrough' heart failure device improves heart function in patients with late-stage diseaseA new device on the market for patients with heart failure is the first device in cardiology to receive a “breakthrough” designation by the Food and Drug Administration.
Weiterlesen »
FDA approves first postpartum depression drug. It works quickly but costs over $20K, report saysBrexanolone, sold as Zulresso, is delivered as a continuous IV infusion over 60 hours. It reportedly works quickly and costs $20,000 or more.
Weiterlesen »
Levi Strauss shares soar after company's second IPO — four experts reactLevi Strauss' initial public offering marks a new era for the 166-year-old denim company, Wall Street experts say.
Weiterlesen »
Levi Strauss shares soar 35% after openLevi Strauss & Co. is a publicly-traded company again, with shares opening at $22.22, 31% above the anticipated IPO price and reaching as high as 35%...
Weiterlesen »
G-III Apparel shares soar 8% premarket as profit blows past estimatesG-III Apparel Group Ltd.'s shares soared 8% in premarket trade Thursday, after the company blew past profit estimates for its fiscal fourth quarter and...
Weiterlesen »
Share buybacks soar to a record topping $800 billion — bigger than a Facebook or Exxon MobilShare repurchases have seen four straight quarters of increases and hit a record $806 billion in 2018, according to S&P Dow Jones Indices.
Weiterlesen »
Hibbett Sports shares soar premarket as earnings blow past estimatesHibbett Sports Inc. shares soared 15% in premarket trade Friday, after the sporting goods retailer blew past estimates for the fourth quarter and offered...
Weiterlesen »
Biogen scraps Alzheimer drug trials, shares slump by a quarterBiogen and partner Eisai Co Ltd are ending two late-stage trials testing the exp...
Weiterlesen »